In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $23.00. The company’s shares opened today at $4.00.
According to TipRanks, Gershell is an analyst with an average return of -9.8% and a 32.37% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Viridian Therapeutics, and Soleno Therapeutics.
PDS Biotechnology has an analyst consensus of Strong Buy, with a price target consensus of $20.00, implying a 400.00% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $13.65 and a one-year low of $3.22. Currently, PDS Biotechnology has an average volume of 542.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PDS Biotechnology (PDSB) Company Description:
PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded on March 15, 2019 and is headquartered in Berkeley Heights, NJ.
Read More on PDSB:
- PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Naïve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA® (pembrolizumab)
- PDS announces interim 24-month data from VERSATILE-002 Phase 2 trial of PDS0101
- PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
- PDS Biotechnology announces data on PDS0101 combined with chemoradiotherapy
- PDS Biotech to Present at the LD Micro Main Event XVI
